SOURCE: World Street Fundamentals

September 20, 2011 10:01 ET

Factors Moving Markets, Worldwide View - Equity Research on Sangamo Biosciences, Inc. and Alnylam Pharmaceuticals, Inc.

HONG KONG--(Marketwire - Sep 20, 2011) - Today, released its industry report highlighting Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Full fundamental and technical analysis is available at

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

World Street Fundamentals has highlighted Sangamo Biosciences, Inc. for its current position within the healthcare industry. Sangamo BioSciences, Inc. (Sangamo) is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs), a naturally occurring class of proteins, and develop a technology platform. The entire report on Sangamo Biosciences, Inc. (NASDAQ: SGMO) is available here:

World Street has featured Alnylam Pharmaceuticals, Inc. for its development within the healthcare industry. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. The entire report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets.

Contact Information